VirbacXPAR:VIRP +1.10%95 EV-to-FCF is 29.45 as of Jul. 12, 2026, which is 0% below its 10-year median of 29.48. GuruFocus rates XPAR:VIRP with a GF Score™ of 95/100 and a GF Value™ of €365.68 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 562 Drug Manufacturers companies, Virbac ranks worse than 58.19% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Virbac's Enterprise Value is €2,852 Mil.
Virbac's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €97 Mil. Therefore, Virbac's EV-to-FCF for today is 29.45.
The historical rank and industry rank for Virbac's EV-to-FCF or its related term are showing as below:
XPAR:VIRP'
s EV-to-FCF Range Over the Past 10 Years
Min: 14.32 Med: 29.48 Max: 617
Current: 29.45
During the past 13 years, the highest EV-to-FCF of Virbac was 617.00. The lowest was 14.32. And the median was 29.48.
XPAR:VIRP's EV-to-FCF is ranked worse than 58.19% of 562
companies
in the Drug Manufacturers industry
Industry Median: 20.955
vs XPAR:VIRP: 29.45
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-07-12), Virbac's stock price is €320.50.
Virbac's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €18.000. Therefore, Virbac's PE Ratio (TTM) for today is 17.81.
Virbac (XPAR:VIRP) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Virbac's share price for today is €320.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Virbac's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €18.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Virbac EV-to-FCF Related Terms
Virbac EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Virbac's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Virbac's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Virbac EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Virbac's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Virbac's EV-to-FCF falls into.
Virbac's current Enterprise Value is €2,852 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Virbac's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €97 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Virbac (XPAR:VIRP) has a EV-to-FCF of 29.45 as of Jul. 12, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Virbac and its competitors. This is near median its historical median of 29.48. Over the past decade, Virbac's EV-to-FCF has ranged from 14.32 to 617.00. According to the industry distribution chart, Virbac ranks #327 out of 562 companies in the Drug Manufacturers industry, placing it in the top 58.2%.
Is Virbac's EV-to-FCF too high?
Virbac's current EV-to-FCF of 29.45 is near median its 10-year median of 29.48. Over the past 10 years, this metric has ranged from a low of 14.32 to a high of 617.00. The Drug Manufacturers industry median EV-to-FCF is 20.96. Virbac's value of 29.45 is 40.5% above this industry median. Based on the distribution chart, Virbac ranks #327 out of 562 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Virbac has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Virbac's EV-to-FCF compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Virbac ranks #327 out of 562 companies for EV-to-FCF. This places Virbac in the lower half of its industry. The industry median EV-to-FCF is 20.96. Virbac's value of 29.45 is 40.5% above this benchmark. Historically, Virbac's own EV-to-FCF has ranged from 14.32 to 617.00 over the past decade. While the company's 10-year median is 29.48 vs. the industry median of 20.96, Virbac has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.96, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Virbac's current EV-to-FCF of 29.45 is 40.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Virbac and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Virbac's current EV-to-FCF is 29.45, which is near median its own 10-year median of 29.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virbac stock overvalued right now?
Based on GuruFocus' analysis, Virbac (XPAR:VIRP) is currently considered Modestly Undervalued. The stock's GF Value™ is €365.68, compared to a current price of €320.50 — trading 12.4% below its estimated fair value. The current EV-to-FCF is 29.45, which is near median its 10-year median of 29.48 and 40.5% above the Drug Manufacturers industry median of 20.96. Virbac's overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Virbac (XPAR:VIRP), the current EV-to-FCF is 29.45 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Virbac (XPAR:VIRP) Overvalued in 2026?
Based on GuruFocus' analysis, Virbac stock appears to be undervalued.
The current stock price of €320.50 is trading 12.4% below its estimated GF Value™ of €365.68.
GuruFocus considers Virbac to be Modestly Undervalued.
Key valuation signals for XPAR:VIRP:
EV-to-FCF: 29.45 (near median its 10-year median of 29.48)
GF Value™: €365.68 vs. price of €320.50 (12.4% below fair value)
Industry Position: 40.5% above the Drug Manufacturers median (#327 of 562)
No single metric tells the full story. See the XPAR:VIRP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, and it also has its presence in Europe, North America, Far East Asia, India, Africa & Middle East (IMEA), Pacific, and Latin America.
95GF Score
Get the complete analysis for XPAR:VIRP
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:VIRP has been successfully added to your 
